Akili

This week's top stories include providers looking for an extension of the pandemic public health emergency to prep for the end of waivers and flexibilities, and a study finds that using Akili's video game-like intervention led to improved sustained attention.

The study did not find find a significant difference in depression symptoms between the intervention and control group.  

This week's top stories include SCOTUS blocking the Biden Administration vaccination rule for employees of large companies, while upholding a mandate for healthcare workers at facilities that accept Medicare and Medicaid funding, and digital medicine platform Akili plans to go public through merging with SPAC Social Capital Suvretta.

Also: Fitbit may be able to tell you how much you snore, and psychedelic-focused startup Mind Cure Health joins the DTx Alliance. 

The company plans to use the new funds to expand its therapeutics beyond ADHD. 

The digital therapeutic for children's ADHD symptoms received a De Novo clearance last summer.

It's been quite a year for digital, from Akili's de novo clearance to the downfall of 'digital pill' maker Proteus. MobiHealthNews takes a look back at the highlights. 

The long-awaited decision is the first regulatory authorization for Akili, and the first game-based therapeutic that the FDA has greenlit for any condition.

In response to recent COVID-19 guidance, the company is releasing its video game-like treatment to qualifying families at no cost, and without explicitly requiring a doctor's prescription.

The large, multi-site investigation described clear improvement in objective symptoms of pediatric attention deficit, but was a bit muddier when describing subjective measures and long-term efficacy.